Trial Profile
A Phase I-II Study of BIBF 1120 and FOLFOX Compared to Bevacizumab and FOLFOX in First Line Metastatic Colorectal Cancer Patients.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Oct 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 07 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Sep 2011 The trial is ongoing in order to collect overall survival data, according to a Boehringer Ingelheim media release.
- 27 Sep 2011 Interim results reported at the 2011 European Multidisciplinary Cancer Congress, according to a Boehringer Ingelheim media release.